Skip to main content
Fig. 3 | Advances in Rheumatology

Fig. 3

From: Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab

Fig. 3

Change in CXCL13 and sICAM-1 From Baseline to Week 24 by Study and Treatment Arm. a CXCL13. b sICAM-1. BL, baseline; CXCL13, C-X-C motif chemokine ligand 13; DAS28-ESR, Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; MTX, methotrexate; NS, not significant; PBO, placebo; RA, rheumatoid arthritis; sICAM-1, soluble intercellular adhesion molecule-1; TCZ, tocilizumab. * P < 0.01. ** P < 0.001. *** P < 0.0001

Back to article page

Advances in Rheumatology

ISSN: 2523-3106